Actively Recruiting
Molecular and Cellular Basis of Severe Forms of Dengue in Sickle Cell Patients
Led by Centre Hospitalier Universitaire de la Guadeloupe · Updated on 2025-06-03
130
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Dengue virus (DENV) belongs to the genus of Flavivirus transmitted by the mosquito Aedes aegypti and is responsible for an infectious disease associated with different forms and severities such as dengue hemorrhagic fever or shock syndrome. Several recent reports have shown that sickle cell patients exhibited an increased risk of developing severe forms of dengue episodes compared to non-sickle cell subjects. Furthermore, among major sickle cell syndromes, these studies suggest that SC patients are at the highest risk of death during these infectious episodes although this sickle cell syndrome is generally associated with a more moderate expression of sickle cell disease. However, the mechanisms involved remain unknown to date. The aim of the present study is to identify the molecular and cellular basis of this increased severity of dengue in SC patients. We hypothesize an exacerbation during DENV infection of the inflammatory response in SC patients compared to SS patients.
CONDITIONS
Official Title
Molecular and Cellular Basis of Severe Forms of Dengue in Sickle Cell Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with SS or SC sickle cell disease or controls with hemoglobin AA
- Diagnosis of sickle cell disease confirmed by electrophoresis or HPLC in a reference laboratory
- Age between 6 and 25 years at inclusion
- Clinically in a steady state at inclusion (no complications in the last month and no transfusions in the past three months)
- Patients followed at the sickle cell center of Guadeloupe (University hospital of Guadeloupe, Pointe-�e0-Pitre)
- Patients or legal representatives of minors provide written informed consent in accordance with the Declaration of Helsinki
- Patients affiliated with national social security
- Control group (AA subjects) recruited among volunteers by posters
You will not qualify if you...
- Patients with SS or SC sickle cell disease or controls with hemoglobin AA
- Diagnosis of sickle cell disease confirmed by electrophoresis or HPLC in a reference laboratory
- Age between 6 and 25 years at inclusion
- Clinically in a steady state at inclusion (no complications in the last month and no transfusions in the past three months)
- Patients followed at the sickle cell center of Guadeloupe (University hospital of Guadeloupe, Pointe-�e0-Pitre)
- Patients or legal representatives of minors provide written informed consent in accordance with the Declaration of Helsinki
- Patients affiliated with national social security
- Control group (AA subjects) recruited among volunteers by posters
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chu de La Guadeloupe
Pointe-à-Pitre, Guadeloupe, 97159
Actively Recruiting
Research Team
V
Valérie Hamony Soter
CONTACT
M
Mélanie petapermal
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here